Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193057 | 0.79 | TAAR1 (0.32) | TAAR1ENPP2 | |
| SCHEMBL4469629 | 0.79 | ENPP2 (0.39) | TAAR1ENPP2 | |
| SCHEMBL31652639 | 0.73 | TAAR1 (0.70) | TAAR1KDM4EALDH1A1ENPP2 | |
| SCHEMBL29650231 | 0.72 | F11 (0.45) | F11KDM4EALDH1A1ENPP2 | |
| SCHEMBL2722490 | 0.72 | F11 (0.45) | F11KDM4EALDH1A1ENPP2 | |
| SCHEMBL177479 | 0.72 | CES2 (0.42) | KDM4EALDH1A1ENPP2 | |
| SCHEMBL857045 | 0.72 | TAAR1 (0.42) | TAAR1ALDH1A1 | |
| SCHEMBL28837730 | 0.71 | F11 (0.48) | TAAR1F11ALDH1A1ENPP2 | |
| SCHEMBL20606030 | 0.71 | PARP1 (0.36) | KDM4EALDH1A1ENPP2 | |
| Hydrochloric Acid SCHEMBL17645949 | 0.71 | F11 (0.48) | F11KDM4EALDH1A1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | TAAR1 3566/4885F11 2004/4885KDM4E 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.